There is no effect on 30 day mortality following early intravenous administration of magnesium sulphate to high risk patients with ST-elevation myocardial infarction (STEMI), a large international trial has shown.
“In view of the totality of the available evidence, in current coronary care practice, there is no indication for the routine administration of intravenous magnesium in patients with STEMI,” is the consensus of clinicians taking part in the Magnesium in Coronaries (MAGIC) trial, declares Dr Elliott Antman, Cardiovascular Division, Brigham & Women’s Hospital, Boston, Massachusetts, United States.
Although mortality among STEMI patients has dropped over recent decades, short-term mortality remains high in two subgroups: those who are not eligible for reperfusion therapy, and those over 65 who receive reperfusion therapy, the clinicians point out. Over the past 22 years, 68,684 patients have been studied in a series of 14 randomized trials of magnesium — a relatively unique situation for investigational therapies in patients with STEMI, ” they add. However, the results are both conflicting and controversial.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!